Cone Rod Dystrophy Market Size, Share, and Industry Analysis, By Drug Type (Vitamins, Antioxidants, Omega-3, and Others), By Form (Tablets, Capsules, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The cone rod dystrophy market is witnessing significant growth due to the increasing prevalence of the condition and related diseases such as scotoma, night blindness, and others. Cone rod dystrophy is a genetically inherited condition resulting in irreversible vision impairment and currently lacks proven treatments. However, potential treatments include nutritional supplements, optical/vision devices, and gene therapy. Among these, nutritional supplements are projected to depict a significant market position due to the widespread availability and low associated risk, which makes them a favorable option.

• According to data published by the International Agency for the Prevention of Blindness in 2020, about 2 to 3 billion people need assistance in 2020 to optimize their vision so that they can function in society.

Download Free sample to learn more about this report.

Cone Rod Dystrophy Market Driver

Increasing Disease Prevalence to Propel the Treatment Demand

In the last few years, there has been a significant rise in instances of cone rod dystrophy, a condition that impacts about 2 million people globally. This ailment is a leading factor in causing vision loss among adults of working age. The increasing prevalence of cone rod dystrophy is leading to a growing demand for the development of tailored therapies and interventions to address this condition.

• For instance, according to an article published by MJH Life Sciences in October 2023, approximately 4.5 million people worldwide were affected by inherited retinal diseases.

Cone Rod Dystrophy Market Restraint

Lack of Approved Treatments May Hamper the Market Growth

The complex genetic bases of cone-rod dystrophy pose significant challenges in the development of treatment options, with current approaches being rather limited. There are a wide range of mutations that can cause retinal dystrophies and mutation in the gene can result in varying disease severities, complicating the development of targeted therapies.

• For instance, in March 2023, according to an article published by NCBI, over 270 genes are phenotypically associated with different retinal dystrophies, of which mutations in 34 genes are known to cause cone-rod dystrophy. 

Cone Rod Dystrophy Market Opportunity

Rising Research and Development to Introduce Novel Therapies May Contribute to Market Growth

Research and development on the efficacy and safety of various treatments including supplements to slow down blindness in patients with cone rod dystrophy is estimated to form new market growth opportunities. The ongoing research can lead to the development of novel formulations and delivery methods, further increasing the market for these treatments.

• For instance, in April 2020, Life Science Alliance LLC published an article stating that the genetic deletion of the SARM1 gene may contribute to the survival of cone and rod photoreceptor cells in individuals affected by cone rod dystrophy.

Segmentation

Key Insights

• Prevalence of Key Diseases, By Key Countries, 2023
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches)
• Overview: Current Treatment Practices for Cone Rod Dystrophy
• Impact of COVID-19 on the Market 

Analysis by Drug Type

By drug type, the market is subdivided into vitamins, antioxidants, omega-3, and others.

The vitamins segment is expected to hold a prominent share of the global market. Vitamins are widely used for eye health due to their higher efficacy and cost-effectiveness. In addition, the vitamins are prescribed as a preventative measure to individuals with cone rod dystrophy to attenuate further complications.

• For instance, in 2022, Ipsos conducted a survey revealing that approximately 46.0% of the European population consumed vitamin D within a year. Out of this, 5.0% of people consumed these supplements to maintain their eye health.

Analysis by Form

By form, the market is categorized into tablets, capsules, and others.

The tablets segment is anticipated to hold a substantial share in the global market. Tablets offer convenience, precise dosage delivery, and an extended shelf life, making them the preferred choice over other forms and contributing to their high demand in the global market. Additionally, new product launches in the form of tablets contribute to market expansion.

• For instance, in February 2023, Herbalife International of America, Inc. launched ‘Ocular Defense,’ its first product in the eye health segment, in tablet form to help maintain normal vision.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The online pharmacies segment is anticipated to hold a significant share of the market over the forecast period. This is due to new launches of online pharmacies providing discounts on these medicines and the convenience given to patients in terms of getting these supplements.

• For instance, in December 2020, Honeybee Health Inc., an online pharmacy, announced that it would sell premium supplements for eye health and other conditions.

Regional Analysis

To get more information on the regional analysis of this market, Download Free sample

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

In the U.S., the market for cone rod dystrophy treatment holds a notable revenue share. The growth of the market is attributed to the increasing awareness of inherited retinal diseases.

• For instance, in 2022, Fighting Blindness Canada, a charity funding vision research in Canada, announced September as an Inherited Retinal Disease awareness month. This initiative helped to spread awareness about cone rod dystrophy in people.

In the Middle East & Africa, the market growth can be attributed to a substantial number of ophthalmologists providing this treatment to individuals suffering from the condition.

• For instance, according to an article published by BioMed Central Ltd, in January 2023, there were 2,608 registered ophthalmologists in Saudi Arabia. Hence, the increasing number of ophthalmologists providing these supplements for the management of cone rod dystrophy can contribute to the market growth in the region.

In the Asia Pacific region, the Australia market is expected to expand over the forecast period due to the prevalence of inherited retinal diseases, which leads to visual impairment across all age groups. The current situation highlights the urgent requirement to develop novel treatments and distribute resources for the support of individuals with low vision, such as supplements to improve and manage their eyesight.

• For instance, according to an article published by the National Library of Medicine in May 2021, the prevalence of cone rod dystrophy in working-age adults was 66.7% in Australia.

Key Players Covered

The report analyzes key industry players offering supplements to preserve vision and overall eye health in cases of cone rod dystrophy. In terms of competition, the market has the presence of a diverse set of companies.

The report includes the profiles of the following key players:

• Amway Corp. (U.S.)
• Nordic Naturals (U.S.)
• Abbott (U.S.)
• Zero Harm (India)
• Blackmores (Australia)
• TEREZIA COMPANY s.r.o. (Czechia)
• Oak Pharma (Belgium)
• Physician's Choice (U.S.)
• Bausch + Lomb (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japan)

Key Industry Developments

• In May 2024, HealthyCell announced the launch of its new Eye Health MicroGel supplement, which promotes visual acuity and supports overall retinal health.
• In April 2022, Wellbeing Nutrition launched the world's first natural eye vitamin, Eye Care Melts, a supplement developed under the global brand Melts to maintain eyesight.